Versor Investments LP Grows Stock Holdings in Repligen Corporation $RGEN

Key Points

• Versor Investments LP significantly increased its stake in Repligen Corporation by 210.2% in the first quarter, acquiring an additional 7,077 shares and valuing its total holdings at approximately $1.33 million.
• Insider trading activity includes Director Martin D. Madaus purchasing 1,800 shares at an average price of $112.13, reflecting confidence in the company despite only 1.20% of stock being owned by insiders.
• Repligen's stock currently holds a consensus rating of "Moderate Buy" from analysts, with target prices ranging from $160.00 to $204.00.

Versor Investments LP grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 210.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 10,444 shares of the biotechnology company's stock after purchasing an additional 7,077 shares during the period. Versor Investments LP's holdings in Repligen were worth $1,329,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new position in Repligen in the 1st quarter worth approximately $165,000. Roubaix Capital LLC purchased a new position in Repligen in the 1st quarter worth approximately $4,437,000. Alliance Wealth Advisors LLC UT raised its holdings in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 89 shares during the last quarter. Ethic Inc. raised its holdings in Repligen by 195.9% in the 1st quarter. Ethic Inc. now owns 5,065 shares of the biotechnology company's stock worth $651,000 after acquiring an additional 3,353 shares during the last quarter. Finally, Fox Run Management L.L.C. raised its holdings in Repligen by 306.6% in the 1st quarter. Fox Run Management L.L.C. now owns 18,848 shares of the biotechnology company's stock worth $2,398,000 after acquiring an additional 14,213 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director directly owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Repligen Trading Down 1.8%

Shares of RGEN stock opened at $124.35 on Monday. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The firm has a fifty day moving average price of $122.50 and a 200-day moving average price of $132.49. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The company has a market cap of $7.00 billion, a price-to-earnings ratio of -497.38, a PEG ratio of 2.29 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period in the previous year, the firm earned $0.40 EPS. The company's revenue was up 14.8% on a year-over-year basis. As a group, equities analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

RGEN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Wells Fargo & Company cut their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Finally, Royal Bank Of Canada lifted their target price on shares of Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.